Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of.
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 14, 2022, Health Canada has authorized TECENTRIQ® (atezolizumab) as - Click here if this is your press release! - Travel News | eTurboNews | eTN
An international research collaboration says it has found evidence pembrolizumab can reverse HIV latency – the ability for the virus to 'hide' inside cells of people living with HIV on antiretroviral therapy
(Reuters) - Researchers studying Merck & Co Inc's cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace t.
Investegate announcements from F. Hoffmann-La Roche Ltd, New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq
Investegate announcements from F. Hoffmann-La Roche Ltd, US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival
New Phase III data support the benefit of Roche's Tecentriq in early-stage lung cancer dkoding.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dkoding.in Daily Mail and Mail on Sunday newspapers.